TY - JOUR
T1 - Molecular pathogenesis of progression to myeloid leukemia from TET-insufficient status
AU - Shrestha, Raksha
AU - Sakata-Yanagimoto, Mamiko
AU - Maie, Koichiro
AU - Oshima, Motohiko
AU - Ishihara, Masatomo
AU - Suehara, Yasuhito
AU - Fukumoto, Kota
AU - Nakajima-Takagi, Yaeko
AU - Matsui, Hirotaka
AU - Kato, Takayasu
AU - Muto, Hideharu
AU - Sakamoto, Tatsuhiro
AU - Kusakabe, Manabu
AU - Nannya, Yasuhito
AU - Makishima, Hideki
AU - Ueno, Hiroo
AU - Saiki, Ryunosuke
AU - Ogawa, Seishi
AU - Chiba, Kenichi
AU - Shiraishi, Yuichi
AU - Miyano, Satoru
AU - Mouly, Enguerran
AU - Bernard, Olivier A.
AU - Inaba, Toshiya
AU - Koseki, Haruhiko
AU - Iwama, Atsushi
AU - Chiba, Shigeru
N1 - Publisher Copyright:
© 2020 by The American Society of Hematology.
PY - 2020/3/10
Y1 - 2020/3/10
N2 - Loss-of-function mutations in ten-eleven translocation-2 (TET2) are recurrent events in acute myeloid leukemia (AML) as well as in preleukemic hematopoietic stem cells (HSCs) of age-related clonal hematopoiesis. TET3 mutations are infrequent in AML, but the level of TET3 expression in HSCs has been found to decline with age. We examined the impact of gradual decrease of TET function in AML development by generating mice with Tet deficiency at various degrees. Tet2f/f and Tet3f/f mice were crossed with mice expressing Mx1-Cre to generate Tet2f/wtTet3f/fMx-Cre1 (T2DT3), Tet2f/fTet3f/wtMx-Cre1 (DT2T3), and Tet2f/f Tet3f/f Mx-Cre1 (DT2DT3) mice. All DT2DT3 mice died of aggressive AML at a median survival of 10.7 weeks. By comparison, T2DT3 and DT2T3 mice developed AML at longer latencies, with a median survival of ;27 weeks. Remarkably, all 9 T2DT3 and 8 DT2T3 mice with AML showed inactivation of the remaining nontargeted Tet2 or Tet3 allele, respectively, owing to exonic loss in either gene or stop-gain mutations in Tet3. Recurrent mutations other than Tet3 were not noted in any mice by whole-exome sequencing. Spontaneous inactivation of residual Tet2 or Tet3 alleles is a recurrent genetic event during the development of AML with Tet insufficiency.
AB - Loss-of-function mutations in ten-eleven translocation-2 (TET2) are recurrent events in acute myeloid leukemia (AML) as well as in preleukemic hematopoietic stem cells (HSCs) of age-related clonal hematopoiesis. TET3 mutations are infrequent in AML, but the level of TET3 expression in HSCs has been found to decline with age. We examined the impact of gradual decrease of TET function in AML development by generating mice with Tet deficiency at various degrees. Tet2f/f and Tet3f/f mice were crossed with mice expressing Mx1-Cre to generate Tet2f/wtTet3f/fMx-Cre1 (T2DT3), Tet2f/fTet3f/wtMx-Cre1 (DT2T3), and Tet2f/f Tet3f/f Mx-Cre1 (DT2DT3) mice. All DT2DT3 mice died of aggressive AML at a median survival of 10.7 weeks. By comparison, T2DT3 and DT2T3 mice developed AML at longer latencies, with a median survival of ;27 weeks. Remarkably, all 9 T2DT3 and 8 DT2T3 mice with AML showed inactivation of the remaining nontargeted Tet2 or Tet3 allele, respectively, owing to exonic loss in either gene or stop-gain mutations in Tet3. Recurrent mutations other than Tet3 were not noted in any mice by whole-exome sequencing. Spontaneous inactivation of residual Tet2 or Tet3 alleles is a recurrent genetic event during the development of AML with Tet insufficiency.
UR - http://www.scopus.com/inward/record.url?scp=85082335007&partnerID=8YFLogxK
U2 - 10.1182/bloodadvances.2019001324
DO - 10.1182/bloodadvances.2019001324
M3 - Article
C2 - 32126143
AN - SCOPUS:85082335007
SN - 2473-9529
VL - 4
SP - 845
EP - 854
JO - Blood Advances
JF - Blood Advances
IS - 5
ER -